Beeline Medicines Corporation, a clinical-stage biotechnology company focused on developing and delivering category-leading precision therapies to transform the lives of people with autoimmune and inflammatory diseases, announced the closing of a $126.3 million Series A extension, bringing its total Series A financing round to $426.3 million.

The funding came from existing shareholders and investors, including Bain Capital, Canada Pension Plan Investment Board (CPP Investments), and Bristol Myers Squibb, and included participation from certain members of the Company's management team. The proceeds from the upsized Series A will support the initiation of several clinical studies across the Company's broad immunology portfolio, including planned pivotal development of its lead program, afimetoran, in lupus.